6-Month Follow-Up validates Zoledronic Acid and CaS/HA Augmentation for Enhanced Bone Formation in Osteoporotic Trochanteric Fractures

MD PhD  Vetra Markevičiūtė, Department of Orthopedics and Traumatology, Lithuanian University of Health Sciences, Kaunas, has recently performed an additional radiographic and clinical follow up (minimum 6 months) of zoledronic acid combined with CaS/HA augmentation in osteoporotic trochanteric fractures from the cohort published in. Systemically administered zoledronic acid activates locally implanted synthetic hydroxyapatite particles enhancing peri-implant bone formation: A regenerative medicine approach to improve fracture fixation. Acta Biomaterialia 2024 Apr 15:179:354-370.

“ Vetra Markevičiūtė concluded that these findings confirm the predicable outcomes previously published. 14 of 20 osteoporotic trochanteric fractures reported in the study were available for follow up. According to the AO classification, there were 11 A1 and 3 A2 femoral fractures (1 A2 in the control group, 2 A2 in the CaS/HA group).  All had healed with no local or systemic complications. 2 patients in the control group had died. 4 were lost to follow up. In 8 patients with CaS/HA augmentation the hip screws were stable with no migration in the femoral head. In 6 non-augmented patients 2 had minor screw migration.

Based on positive outcome in several published clinical fracture trials from the centre in Kaunas, CaS/HA augmentation of unstable trochanteric fractures operated in combination with postoperative bisphosphonates should be a next step-in Real-World Evidence studies.”